Kura Oncology to Report First Quarter 2017 Financial Results
May 08 2017 - 3:05PM
Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced that it will report first
quarter 2017 financial results after the close of U.S. financial
markets on May 15, 2017. Kura Oncology’s management will host a
webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT that day
to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-516-3514 for
domestic callers and 281-973-6129 for international callers and
entering the conference code: 14001186. A live webcast and archive
of the call will be available online from the investor relations
section of the company website at www.kuraoncology.com. A telephone
replay of the call will be available by dialing 855-859-2056 for
domestic callers or 404-537-3406 for international callers and
entering the conference code:
14001186.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura Oncology’s lead drug candidate is
tipifarnib, a farnesyl transferase inhibitor, which is currently
being studied in multiple Phase 2 clinical trials. Kura’s pipeline
also includes KO-947, an ERK inhibitor, currently in a Phase 1
trial, and KO-539, an inhibitor of the menin-MLL protein-protein
interaction, currently in preclinical testing. For additional
information about Kura Oncology, please visit the company’s website
at www.kuraoncology.com.
CONTACT INFORMATION
INVESTOR CONTACT:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
CORPORATE COMMUNICATIONS CONTACT:
Mark Corbae
Vice President
Canale Communications
(619) 849 5375
mark@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024